Yesterday, the Food and Drug Administration (FDA) released a statement concerning the therapeutic benefits of two generic versions of Concerta tablets (methylphenidate hydrochloride extended-release tablets), intended to treat attention-deficit/hyperactivity disorder (ADHD) in adults and children. The agency is asking whether the generic
products are bioequivalent to the brand-name drug. Read the rest of the article from the APA Psychiatric News Alert here.